View Older Stories View More Recent Stories

Jul 26, 2023 07:55AM Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
Jul 20, 2023 04:05PM Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
Jul 13, 2023 08:02AM Ardelyx (ARDX) Announces Acceptance of NDA for Tenapanor for Hyperphosphatemia in China
Jul 13, 2023 08:00AM Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
Jun 29, 2023 04:09PM Ardelyx, Inc. Reports Employment Inducement Grants
Jun 5, 2023 08:00AM Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
May 31, 2023 08:00AM Ardelyx to Present at the Jefferies 2023 Healthcare Conference
May 23, 2023 04:05PM Ardelyx, Inc. Reports Employment Inducement Grants
May 17, 2023 07:30AM Ardelyx (ARDX) Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH
May 17, 2023 07:30AM Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
May 15, 2023 04:05PM Ardelyx, Inc. Reports Employment Inducement Grants
May 9, 2023 08:03AM Ardelyx (ARDX) Presents Positive Data at DDW 2023 on IBSRELA, a First-In-Class Treatment for IBS-C in Adults
May 9, 2023 08:00AM Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 3, 2023 04:02PM Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
May 1, 2023 08:00AM Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
May 1, 2023 08:00AM Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
Apr 26, 2023 08:00AM Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
Apr 26, 2023 08:00AM Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
Apr 18, 2023 08:03AM Ardelyx (ARDX) Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH (tenapanor)
Apr 18, 2023 08:00AM Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
Apr 18, 2023 08:00AM Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
Apr 13, 2023 04:05PM Ardelyx, Inc. Reports Employment Inducement Grants
Apr 13, 2023 04:05PM Ardelyx, Inc. Reports Employment Inducement Grants
Apr 12, 2023 04:07PM Ardelyx (ARDX) Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH
Apr 12, 2023 04:05PM Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
Apr 12, 2023 04:05PM Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
Mar 2, 2023 04:02PM Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Mar 2, 2023 04:02PM Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Feb 28, 2023 08:00AM Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
Feb 28, 2023 08:00AM Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
Feb 27, 2023 08:15AM Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference
Feb 27, 2023 08:15AM Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference
Feb 23, 2023 08:00AM Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
Feb 23, 2023 08:00AM Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
Feb 2, 2023 04:20PM Ardelyx, Inc. Reports Employment Inducement Grants
Dec 29, 2022 07:00AM Ardelyx (ARDX) Granted FDA Appeal for XPHOZAH
Dec 29, 2022 07:00AM FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
Dec 23, 2022 05:58PM Ardelyx, Inc. Reports Employment Inducement Grants
Dec 19, 2022 05:11AM Ardelyx (ARDX) Provides Update on FDA Appeal for XPHOZAH
Dec 16, 2022 07:51PM Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
Nov 22, 2022 08:00AM Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference
Nov 17, 2022 05:54AM Ardelyx (ARDX) Announces 9:4 FDA Vote AdCom Vote Favoring XPHOZAH
Nov 16, 2022 06:29PM Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialys
Nov 16, 2022 09:02AM FDA AdCom Continues to Discuss Ardelyx's (ARDX) Discuss XPHOZAH
Nov 16, 2022 09:02AM FDA AdCom Continues to Discuss Ardelyx's (ARDX) Discuss XPHOZAH
Nov 16, 2022 09:00AM Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
May 2, 2022 04:01PM Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
Apr 25, 2022 08:54AM Pre-Open Stock Movers 04/25: PS Business Parks and Twitter Jump on Deal News; Axsome Sinks on Expected CRL (more...)
Apr 30, 2021 09:28AM Pre-Open Stock Movers 04/30: (LAUR) (WDC) (TEAM) Higher; (MVIS) (ARDX) (TWTR) Lower (more...)
Apr 29, 2021 05:31PM After-Hours Stock Movers 04/29: (TEAM) (LAUR) (AMZN) Higher; (MVIS) (ARDX) (CRUS) Lower (more...)
View More Recent Stories View Older Stories